Open AccessHer-2 neu (Cerb-B2) expression in fine needle aspiration samples of breast carcinoma: A pilot study comparing FISH, CISH and immunocytochemistry
Author(s) -
Kusum Kapila,
Shafiqa Al-Awadhi,
Francis Im
Publication year - 2011
Publication title -
journal of cytology/journal of cytology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.267
H-Index - 19
eISSN - 0974-5165
pISSN - 0970-9371
DOI - 10.4103/0970-9371.80731
Subject(s) - cish , chromogenic in situ hybridization , immunohistochemistry , medicine , pathology , breast carcinoma , breast cancer , fluorescence in situ hybridization , trastuzumab , fine needle aspiration , gene duplication , carcinoma , cancer , in situ hybridization , oncology , gene expression , biopsy , gene , biology , biochemistry , chromosome
Breast cancers with Her-2 neu gene amplification are recognized as important markers for aggressive disease and targets which respond to therapy with trastuzumab. Her-2 neu testing on histological sections is routinely performed to select patients who may benefit from anti- Her-2 neu therapy. Few reports are available which document Her-2 neu status on fine needle aspirates (FNA).